Qube Research & Technologies (QRT)

Qube Research & Technologies (QRT)’s Eupraxia Pharmaceuticals EPRX Stock Holding History

Qube Research & Technologies (QRT)’s Portfolio EPRX Stock Details EPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$226K	Buy	+34,237	New	+$236K	﹤0.01%	2856

Other funds holding EPRX

Beutel, Goodman & Co Toronto, Ontario, Canada $13.6B AUM 17.82% 1-Year Est. Return

Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return

Balyasny Asset Management

Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return

Scotia Capital Toronto, Ontario, Canada $26.8B AUM 33.07% 1-Year Est. Return

PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return

Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return

Qube Research & Technologies (QRT)'s EPRX Position: Q2 2026 in Review

Qube Research & Technologies (QRT) opened a new position in Eupraxia Pharmaceuticals (EPRX) in Q2 2026: 34,237 shares worth $226K. The stake represents ﹤0.01% of the portfolio and ranks #2856 among its holdings.

68 funds tracked by Wall St. Rank hold EPRX as of Q2 2026.

Qube Research & Technologies (QRT) held 34,237 shares of Eupraxia Pharmaceuticals worth $226K as of Q2 2026.
Eupraxia Pharmaceuticals was a new Qube Research & Technologies (QRT) position in Q2 2026.
Eupraxia Pharmaceuticals made up ﹤0.01% of Qube Research & Technologies (QRT)'s portfolio in Q2 2026, its #2856 holding.
68 funds tracked by Wall St. Rank held Eupraxia Pharmaceuticals as of Q2 2026.

Based on Qube Research & Technologies (QRT)'s 13F filing for Q2 2026, filed 14 Aug 2026.